ArticleCirculation. Cardiovascular genetics2017
Registry-linked trialOpen access · diamondAbstract read
In one paragraph
Article in Circulation. Cardiovascular genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06675994 (Evaluation of PCSK9 Enzyme in Non-Cholesterol Biological Pathways), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of PCSK9 Enzyme in Non-Cholesterol Biological Pathways: In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme
PMID 26896437PMID 31511398PMID 35078371PMID 34681838PMID 33026143PMID 32252393PMID 31218482PMID 31034291PMID 29471945PMID 27810295PMID 26092101PMID 16286165other papers from this trial
Open the trial in the graphWho cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Role of PCSK9 in breast cancer: a systematic review of its mechanistic pathways and clinical relevance.Frontiers in pharmacology · 2026Pooled it
- Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis.Bioscience reports · 2019Pooled it
- Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?Journal of internal medicine · 2026Review
- A Genome-First Study of Familial Hypercholesterolemia Comparing African and European Ancestry Individuals.Circulation · 2026Article
- Role of Hyperlipidemia-RelatedMolecular syndromology · 2026Article
- The Roles of PCSK9 in Alzheimer's Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence.Life (Basel, Switzerland) · 2025Review
- Population molecular genetics in Brazil: From genomic databases and research to the implementation of precision medicine.Journal of community genetics · 2025Review
- Investigating the sources of variable impact of pathogenic variants in monogenic metabolic conditions.Nature communications · 2025Article
- PCSK9 in Vascular Aging and Age-Related Diseases.Aging and disease · 2025Review
- Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition.Nutrients · 2024Review
- Correlation of Eight (8) Polymorphisms and Their Genotypes with the Risk Factors of Cardiovascular Disease in a Black Elderly Population.Current issues in molecular biology · 2024Article
- Effect of diet and genotype on the lipidome of mice with altered lipoprotein metabolism.iScience · 2024Article
- Is It Ever Wise to Edit Wild-Type Alleles? Engineered CRISPR Alleles Versus Millions of Years of Human Evolution.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations.Frontiers in pharmacology · 2024Review
- Applications of Genome Editing Technologies in CAD Research and Therapy with a Focus on Atherosclerosis.International journal of molecular sciences · 2023Review
- Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous population.Cell genomics · 2023Article
- Associations of lipids and lipid-lowering drugs with risk of stroke: a Mendelian randomization study.Frontiers in neurology · 2023Article
- Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop.American journal of preventive cardiology · 2022Review
- Inclisiran: How Widely and When Should We Use It?Current atherosclerosis reports · 2022Review
- New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.Current cardiovascular risk reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 5 institutions in 9 countries.
Shia T KentFor the author affiliations, please see the Appendix.
Robert S RosensonFor the author affiliations, please see the Appendix.
Christy L AveryFor the author affiliations, please see the Appendix.
Yii-Der I ChenFor the author affiliations, please see the Appendix.
Adolfo CorreaFor the author affiliations, please see the Appendix.
Steven R CummingsFor the author affiliations, please see the Appendix.
L Adrienne CupplesFor the author affiliations, please see the Appendix.
Mary CushmanFor the author affiliations, please see the Appendix.
Daniel S EvansFor the author affiliations, please see the Appendix.
Vilmundur GudnasonFor the author affiliations, please see the Appendix.
Tamara B HarrisFor the author affiliations, please see the Appendix.
George HowardFor the author affiliations, please see the Appendix.
Marguerite R IrvinFor the author affiliations, please see the Appendix.
Suzanne E JuddFor the author affiliations, please see the Appendix.
J Wouter JukemaFor the author affiliations, please see the Appendix.
Leslie LangeFor the author affiliations, please see the Appendix.
Emily B LevitanFor the author affiliations, please see the Appendix.
Xiaohui LiFor the author affiliations, please see the Appendix.
Yongmei LiuFor the author affiliations, please see the Appendix.
Wendy S PostFor the author affiliations, please see the Appendix.
Iris PostmusFor the author affiliations, please see the Appendix.
Bruce M PsatyFor the author affiliations, please see the Appendix.
Jerome I RotterFor the author affiliations, please see the Appendix.
Monika M SaffordFor the author affiliations, please see the Appendix.
Colleen M SitlaniFor the author affiliations, please see the Appendix.
Albert V SmithFor the author affiliations, please see the Appendix.
James D StewartFor the author affiliations, please see the Appendix.
Stella TrompetFor the author affiliations, please see the Appendix.
Fangui SunFor the author affiliations, please see the Appendix.
Ramachandran S VasanFor the author affiliations, please see the Appendix.
J Michael WoolleyFor the author affiliations, please see the Appendix.
Eric A WhitselFor the author affiliations, please see the Appendix.
Kerri L WigginsFor the author affiliations, please see the Appendix.
James G WilsonFor the author affiliations, please see the Appendix.
Paul MuntnerFor the author affiliations, please see the Appendix. pmuntner@uab.edu.
TiGenix (Spain) · ESApple (Israel) · ILCorixa Corporation · USEstonian Academy of Security Sciences · EEUnited Nations · US
Funding
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MVCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0MInstitute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8MInstitute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MUCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MCTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0MTransgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrea L Hevener · 2003 to 2026
$40.4MTracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI COMPRETTA, CAROLINE E. · 2016 to 2025
$38.2MClinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2MGenome-Wide Association Analysis in Essential Hypertension (FEHGAS study)R01HL086694 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ARAVINDA CHAKRAVARTI · 2007 to 2026
$21.2MUniversity of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5MEpidemiology of Venous Thrombosis & Pulmonary EmbolismR01HL059367 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI TANG, WEIHONG · 1998 to 2024
$11.8MNCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001881NCRR NIH HHS UL1 RR024156NCRR NIH HHS UL1 RR025005NHGRI NIH HHS HHSN268200782096CNHGRI NIH HHS U01 HG004402NHLBI NIH HHS HHSN268200800007CNHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100005GNHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100008INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100011INHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS HHSN268201200036CNHLBI NIH HHS HHSN268201300046CNHLBI NIH HHS HHSN268201300047CNHLBI NIH HHS HHSN268201300048CNHLBI NIH HHS HHSN268201300049CNHLBI NIH HHS HHSN268201300050CNHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS K24 HL111154NHLBI NIH HHS N01 HC025195NHLBI NIH HHS N01 HC055222NHLBI NIH HHS N01 HC085079NHLBI NIH HHS N01 HC085080NHLBI NIH HHS N01 HC085081NHLBI NIH HHS N01 HC085082NHLBI NIH HHS N01 HC085083NHLBI NIH HHS N01 HC085086NHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169NHLBI NIH HHS R01 HL059367NHLBI NIH HHS R01 HL080477NHLBI NIH HHS R01 HL085251NHLBI NIH HHS R01 HL086694NHLBI NIH HHS R01 HL087641NHLBI NIH HHS R01 HL087652NHLBI NIH HHS R01 HL103612NHLBI NIH HHS R01 HL105756NHLBI NIH HHS R01 HL120393NHLBI NIH HHS U01 HL080295NHLBI NIH HHS U01 HL130114NIA NIH HHS N01 AG062101NIA NIH HHS N01 AG062103NIA NIH HHS N01 AG062106NIA NIH HHS R01 AG023629NIA NIH HHS R01 AG032098NIDDK NIH HHS P30 DK063491NIDDK NIH HHS P30 DK079626NIGMS NIH HHS U54 GM115428NINDS NIH HHS U01 NS041588
Abstract
backgroundMETHODS AND
resultsThese 9 studies together included 17 459 blacks with 403 (2.3%) having at least 1 Y142X or C679X variant and 31 306 whites with 955 (3.1%) having at least 1 R46L variant. Unadjusted odds ratios for associations between
conclusions
Indexed as
AgedAged, 80 and overBlack PeopleCholesterol, LDLCohort StudiesCoronary DiseaseFemaleGenetic VariationGenotypeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleOdds RatioPolymorphism, Single NucleotideProportional Hazards ModelsProprotein Convertase 9Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 protein, humanProprotein Convertase 9goalsincidencelipoproteins, LDLmeta-analysismyocardial infarctionpolymorphism, single nucleotidestroke
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06675994ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.